Get Patients with Peripheral Artery Disease Going

Medical Need

Current Treatment Options

  • Exercise: no option in severe PAD
  • Conservative Tx: risk factor reduction (e.g. BP reduction, glucose control, medication) – limited efficacy
  • Intervention: Angioplasty or Vascular Surgery
  • No-option patients: PAD stage IV – foot / leg amputation

Antepulsation

  • Endogenous regeneration of biological bypasses (arteriogenesis)
  • Non-invasive / non-surgical
  • Personalized treatment PAD stage I – IV
  • Bail out in PAD stage IV

Business Model

  • Clear medical need
  • Only enhanced external pro-pulsation on the market
  • Experienced management
  • Intellectual Property Protection
  • Renowned clinical and financial advisors

  • Low development costs through outsourcing
  • Clear regulatory pathway for FDA / CE-Mark
  • Existing reimbursement cases
  • Dramatic growing market in the US and Europe

Get Patients Going

Initial Claudication Distance (ICD)

Absolute Claudication Distance (ACD)

Powered by People

Kai Ollrogge

CEO

Dr. Philipp Hillmeister

Philipp Hillmeister, PhD

CSO

Our Achievements

  • 2020-03-15:  Antepuls GmbH officially founded to get patients with peripheral arterial disease going
  • 2020-02-19:  Clinical Study initiated
  • 2018-06-19:  First Closing of Seed Investment into improving the situation of 5 million people in the EU alone   suffering from peripheral arterial disease (PAD)

Antepuls has been granted eligibility by the BAFA (Federal Office of Economics and Export Control) for INVEST funding. It is a program by the Federal Ministry for Economic Affairs and Energy to subsidize venture capital investments by private investors for young innovative companies. This government support follows the funding measure „Validation of the technological and societal innovation potential of scientific research – VIP+“ of the Federal Ministry of Education and Research (BMBF).